Skip to main content
SpringerLink
Log in

Drug Resistance

  • Chapter
  • First Online:
Origin of Cancers

Part of the book series: Cancer Treatment and Research ((CTAR,volume 154))

  • 939 Accesses

Précis

Elucidation of a stem-cell origin of cancers and drug resistance may steer us away from many well-intentioned but potentially futile treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance [review]. Nat Rev Cancer 5:275–284

    Article  CAS  PubMed  Google Scholar 

  2. Johnstone RW, Cretney E, Smyth MJ (1999) P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 93:1075–1085

    CAS  PubMed  Google Scholar 

  3. Pallis M, Russell N (2000) P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. Blood 95:2897–2904

    CAS  PubMed  Google Scholar 

  4. Baer MR, George SL, Dodge RK et al (2002) Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100:1224–1232

    CAS  PubMed  Google Scholar 

  5. Greenberg PL, Lee SJ, Advani R et al (2004) Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol 22:1078–1086, Erratum in J Clin Oncol 2004;22(13):2747

    Article  CAS  PubMed  Google Scholar 

  6. Zhou S, Schuetz JD, Bunting KD et al (2001) The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7:1028–1034

    Article  CAS  PubMed  Google Scholar 

  7. Good JR, Kuspa A (2000) Evidence that a cell-type-specific efflux pump regulates cell differentiation in Dictyostelium. Dev Biol 220:53–61

    Article  CAS  PubMed  Google Scholar 

  8. Osawa M, Hanada K, Hamada H et al (1996) Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science 273:242–245

    Article  CAS  PubMed  Google Scholar 

  9. Gussoni E, Soneoka Y, Strickland CD et al (1999) Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature 401:390–394

    CAS  PubMed  Google Scholar 

  10. Jackson KA, Mi T, Goodell MA (1999) Hematopoietic potential of stem cells isolated from murine skeletal muscle. Proc Natl Acad Sci USA 96:14482–14486

    Article  CAS  PubMed  Google Scholar 

  11. Hulspas R, Quesenberry PJ (2000) Characterization of neurosphere cell phenotypes by flow cytometry. Cytometry 40:245–250

    Article  CAS  PubMed  Google Scholar 

  12. Cervantes RB, Stringer JR, Shao C et al (2002) Embryonic stem cells and somatic cells differ in mutation frequency and type. Proc Natl Acad Sci USA 99:3586–3590

    Article  CAS  PubMed  Google Scholar 

  13. Myllyperkiö MH, Vilpo JA (1999) Increased DNA single-strand break joining activity in UV-irradiated CD34+ versus CD34− bone marrow cells. Mutat Res 425:169–176

    PubMed  Google Scholar 

  14. Ellis HM, Horvitz HR (1986) Genetic control of programmed cell death in the nematode C. elegans. Cell 44:817–829

    Article  CAS  PubMed  Google Scholar 

  15. McDonnell TJ, Deane N, Platt FM et al (1989) bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57:79–88

    Article  CAS  PubMed  Google Scholar 

  16. Vaux DL, Cory S, Adams JM (1988) Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440–442

    Article  CAS  PubMed  Google Scholar 

  17. Tu S-M, Lopez A, Leibovici D et al (2009) Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy. Cancer 115:2872–2880

    Article  PubMed  Google Scholar 

  18. Goldie JH, Coldman AJ (1979) A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63(11–12):1727–1733

    CAS  PubMed  Google Scholar 

  19. Laird AK (1969) Dynamics of growth in tumors and in normal organisms. Natl Cancer Inst Monogr 30:15–28

    CAS  PubMed  Google Scholar 

  20. Williams SD, Stablein DM, Einhorn LH et al (1987) Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 317:1433–1438

    Article  CAS  PubMed  Google Scholar 

  21. Bonadonna G, Zambetti M, Valagussa P (1995) Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 273:542–547

    Article  CAS  PubMed  Google Scholar 

  22. Fisher RI, DeVita VT, Hubbard SP et al (1979) Prolonged disease-free survival in Hodgkin’s disease with MOPP reinduction after first relapse. Ann Intern Med 90:761–763

    CAS  PubMed  Google Scholar 

  23. Kardinal CG, Perry MC, Korzun AH et al (1988) Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy. A subset analysis of CALGB study 8081. Cancer 61:415–419

    Article  CAS  PubMed  Google Scholar 

  24. Adair F, Berg J, Joubert L et al (1974) Long-term followup of breast cancer patients: the 30-year report. Cancer 33:1145–1150

    Article  CAS  PubMed  Google Scholar 

  25. Ferguson DJ, Meier P, Karrison T et al (1982) Staging of breast cancer and survival rates. An assessment based on 50 years of experience with radical mastectomy. JAMA 248:1337–1341

    Article  CAS  PubMed  Google Scholar 

  26. Brinkley D, Haybrittle JL (1975) The curability of breast cancer. Lancet 2:95–97

    Article  CAS  PubMed  Google Scholar 

  27. Rutqvist LE, Wallgren A, Nilsson B (1984) Is breast cancer a curable disease? A study of 14,731 women with breast cancer from the Cancer Registry of Norway. Cancer 53:1793–1800

    Article  CAS  PubMed  Google Scholar 

  28. Fisher B, Redmond C, Poisson R et al (1989) Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 320:822–828, Erratum in N Engl J Med 1994;330(20):1467

    Article  CAS  PubMed  Google Scholar 

  29. Balch CM, Soong S-J, Bartolucci AA et al (1996) Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 224:255–266

    Article  CAS  PubMed  Google Scholar 

  30. Leighton C, Fisher B, Bauman G et al (1997) Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol 15:1294–1301

    CAS  PubMed  Google Scholar 

  31. Le Cesne A, Judson I, Crowther D et al (2000) Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 18:2676–2684

    PubMed  Google Scholar 

  32. Peters WP, Rosner GL, Vredenburgh JJ et al (2005) Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol 23:2191–2200

    Article  PubMed  Google Scholar 

  33. Sternberg CN, de Mulder PHM, Schornagel JH et al (2001) Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer protocol No. 30924. J Clin Oncol 19:2638–2646

    CAS  PubMed  Google Scholar 

  34. Giaccone G, Dalesio O, McVie GJ et al; European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (1993) Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. J Clin Oncol 11:1230–1240

    CAS  PubMed  Google Scholar 

  35. Markman M, Liu PY, Wilczynski S et al (2003) Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21:2460–2465

    Article  CAS  PubMed  Google Scholar 

  36. Muss HB, Case LD, Richards F 2nd et al (1991) Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med 325:1342–1348

    Article  CAS  PubMed  Google Scholar 

  37. Chapman PB, Einhorn LH, Meyers ML et al (1999) Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17:2745–2751

    CAS  PubMed  Google Scholar 

  38. Thigpen JT, Brady MF, Homesley HD et al (2004) Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 22:3902–3908

    Article  CAS  PubMed  Google Scholar 

  39. Santoro A, Tursz T, Mouridsen H et al (1995) Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13:1537–1545

    CAS  PubMed  Google Scholar 

  40. Ohtsu A, Shimada Y, Shirao K et al (2003) Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21:54–59

    Article  CAS  PubMed  Google Scholar 

  41. Niell HV, Herndon JE II, Miller AA et al (2005) Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 23:3752–3759

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA

    Shi-Ming Tu

Authors
  1. Shi-Ming Tu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shi-Ming Tu .

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Tu, SM. (2010). Drug Resistance. In: Origin of Cancers. Cancer Treatment and Research, vol 154. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-5968-3_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-5968-3_15

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4419-5967-6

  • Online ISBN: 978-1-4419-5968-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation